Skip to Main Content
Skip Nav Destination

Osimertinib Will Be New Standard for Some NSCLCs

June 4, 2024

Abstract: In the international phase III LAURA trial, patients with inoperable EGFR-stage III non–small cell lung cancer that doesn’t worsen during or soon after chemoradiotherapy derived a significant progression-free survival (PFS) benefit with the EGFR-directed therapy osimertinib compared with a placebo. Median PFS was 39.1 months and 5.6 months, respectively, and median duration of response was 36.9 months and 6.5 months, respectively.

You do not currently have access to this content.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal